News
If You're in Your 40s, Consider Buying This Stock
If you're a 40-year-old investor, you're probably not planning on retiring for another 20 years or more. While that may be a bit of a downer for those looking forward to the freedom that....
What Caused Sarepta Therapeutics to Rally 12.6% in September
After reporting early-stage data from a drug candidate for the treatment of Duchenne muscular dystrophy (DMD) on September 6, shares in Sarepta Therapeutics (NASDAQ: SRPT) jumped 12.6% last month,....
3 High-Yield Billionaire Stocks
Billionaire investors know a thing or two about picking stocks. That's why we Fools like to scan our favorite investors' holdings every couple of months to see what they have been buying and....
3 High-Yield Billionaire Stocks
Billionaire investors know a thing or two about picking stocks. That's why we Fools like to scan our favorite investors' holdings every couple of months to see what they have been buying and....
Why Shopify, Momenta Pharmaceuticals, and MBIA Slumped Today
The stock market saw new highs on Wednesday, even though gains for most major benchmarks were extremely small. Investors are trying to balance their enthusiasm about the U.S. economy and potential....
Here's Why Rigel Pharmaceuticals, Inc. Reversed Course Today
Shares of Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) got off to a rocky start this morning, falling more than 8% before the market digested the details of a recently announced share offering. The....
Here's Why Strongbridge Biopharma Fell as Much as 20% Today
Shares of Strongbridge Biopharma (NASDAQ: SBBP) dropped 20% this morning after the rare-disease therapeutic developer announced the pricing of a share offering. The company will sell 4 million....
Here's Why NewLink Genetics Corp. Stock Is Surging Again Today
Shares of NewLink Genetics Corp. (NASDAQ: NLNK), a clinical stage biotech with an oncology focus, are rising in response to a secondary offering that ended up priced much better than anticipated.....
Like a Weed, This Marijuana Stock Catapulted Higher by 34% Last Week
If you're an investor, chances are you're well aware that it's been tough to surpass the returns from marijuana stocks over the past year. In late June, the average trailing 12-month return of the....
3 Top Small-Cap Stocks to Buy in October
Even though Halloween is coming, don't let all small-cap stocks scare you. While it's generally true that smaller businesses present higher risks to investors than larger companies do, they may....
Why Shares in AbbVie Soared 18% in September
A patent victory and pipeline advances that could lead to billions in additional sales helped catapult AbbVie Inc. (NYSE: ABBV) shares 18% higher in September, according to S&P Global Market....
Why Shares in AbbVie Soared 18% in September
A patent victory and pipeline advances that could lead to billions in additional sales helped catapult AbbVie Inc. (NYSE: ABBV) shares 18% higher in September, according to S&P Global Market....
Why Shares in AbbVie Soared 18% in September
A patent victory and pipeline advances that could lead to billions in additional sales helped catapult AbbVie Inc. (NYSE: ABBV) shares 18% higher in September, according to S&P Global Market....
Why PTC Therapeutics, Inc. Dropped Today
PTC Therapeutics (NASDAQ: PTCT) fell 10.9% on Tuesday after disclosing data for RG7916 in patients with Type 2 and Type 3 spinal muscular atrophy (SMA).It's been a roller coaster for PTC....
Intercept Pharmaceuticals, Inc. Was Halved in September, but Presents an Intriguing Opportunity
Shares of Intercept Pharmaceuticals (NASDAQ: ICPT), a small-cap biotech company with a focus on discovering medicines to treat non-viral, progressive liver diseases, lost roughly half of its value....
Why bluebird bio, Inc. Stock Gained 10% in September
Shares of bluebird bio, Inc. (NASDAQ: BLUE), a clinical-stage biotech developing cell-based therapies, rose 10% in September according to data from S&P Global Market Intelligence. Although....
Why bluebird bio, Inc. Stock Gained 10% in September
Shares of bluebird bio, Inc. (NASDAQ: BLUE), a clinical-stage biotech developing cell-based therapies, rose 10% in September according to data from S&P Global Market Intelligence. Although....
Why bluebird bio, Inc. Stock Gained 10% in September
Shares of bluebird bio, Inc. (NASDAQ: BLUE), a clinical-stage biotech developing cell-based therapies, rose 10% in September according to data from S&P Global Market Intelligence. Although....
Is This How Drugmakers Will Kill Biosimilars?
Pfizer (NYSE: PFE) has filed a lawsuit accusing Johnson & Johnson (NYSE: JNJ) of strong-arming insurers into excluding its Remicade biosimilar, Inflectra, from their reimbursement lists. If....
Is This How Drugmakers Will Kill Biosimilars?
Pfizer (NYSE: PFE) has filed a lawsuit accusing Johnson & Johnson (NYSE: JNJ) of strong-arming insurers into excluding its Remicade biosimilar, Inflectra, from their reimbursement lists. If....
After Intepirdine Flunked in Alzheimer’s Disease, Is Axovant Sciences a Buy?
Hope was running high at Axovant Sciences (NASDAQ: AXON) that that teaming up their drug intepirdine with the top-selling Alzheimer's disease treatment, Aricept, could improve patients' lives.....
After Intepirdine Flunked in Alzheimer’s Disease, Is Axovant Sciences a Buy?
Hope was running high at Axovant Sciences (NASDAQ: AXON) that that teaming up their drug intepirdine with the top-selling Alzheimer's disease treatment, Aricept, could improve patients' lives.....
After Intepirdine Flunked in Alzheimer’s Disease, Is Axovant Sciences a Buy?
Hope was running high at Axovant Sciences (NASDAQ: AXON) that that teaming up their drug intepirdine with the top-selling Alzheimer's disease treatment, Aricept, could improve patients' lives.....
Good News and Bad News for Gilead Sciences: Which Carries More Weight?
You knew it wouldn't take too long for euphoria over Gilead Sciences' (NASDAQ: GILD) planned acquisition of Kite Pharma to wear off. The question was whether the next round of news for the big....
Good News and Bad News for Gilead Sciences: Which Carries More Weight?
You knew it wouldn't take too long for euphoria over Gilead Sciences' (NASDAQ: GILD) planned acquisition of Kite Pharma to wear off. The question was whether the next round of news for the big....